View of Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy

Return to Issue Details Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy Download Download PDF